Cannabis Use, Opioid Use Disorder
Conditions
Keywords
opioid use, cannabis
Brief summary
The study will enroll participants with opioid use disorder and participants will reside at the University of Kentucky Hospital for this 6-week inpatient trial. During this time, double-blind doses of cannabis and opioids will be administered. The goal of the project is to determine if cannabis can alter the drive/desire to take opioids.
Interventions
DRUGCannabis
Cannabis is administered three times daily during the active cannabis treatment period.
DRUGPlacebo Cannabis
Matched placebo cannabis is administered three times daily during the placebo treatment period.
DRUGIntranasal Opioid Agonist
Intranasal opioid agonists are administered during sample and self-administration sessions
DRUGOral Opioid Agonist
Oral opioid agonist maintenance doses are administered four times daily throughout study participation.
Sponsors
Shanna Babalonis, PhD
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
* Participants with moderate to severe opioid use disorder who experience opioid withdrawal * No allergies or adverse reactions to cannabis or opioids * Willing to stay inpatient at the UK Hospital research center for approx. 6 weeks
Exclusion criteria
* Individuals seeking treatment for opioid use disorder
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Opioid Self-Administration Trials Completed | Up to 6.5 Weeks | Number of drug-choice trials completed for intranasal opioid agonists during self-administration sessions. |
Countries
United States
Contacts
CONTACTPaul Nuzzo
PRINCIPAL_INVESTIGATORShanna Babalonis, PhD
University of Kentucky, College of Medicine
Outcome results
None listed